NewsBenzingaViridian Therapeutics Announced Phase 1 Results For VRDN-008; Demonstrated Deep And Sustained IGG Reduction Through 8 Weeks After Subcutaneous Dosing, With 74% Reduction At Peak Viridian Therapeutics Announced Phase 1 Results For VRDN-008; Demonstrated Deep And Sustained IGG Reduction Through 8 Weeks After Subcutaneous Dosing, With 74% Reduction At Peak Benzinga 2026.11.09 12:12 (GMT+0) Open on Benzinga Other news Isomorphic Labs Raises $5 Billion for AI Drug Design “AI Stock God” Leopold’s Fund Makes Sweeping Exit From Bitcoin Mining Stocks: IREN Position Slashed 94%, Several Miners Liquidated Wells Fargo: Get Paid to Wait: or Buy at a Discount Is a $1,100 Solana Price Realistic? Bitwise’s Model Has One Big Condition Bitcoin Holds Near $64,800 as ETF Outflow Streak Ends Royal Caribbean Cruises Stock Outlook: Is Wall Street Bullish or Bearish?
“AI Stock God” Leopold’s Fund Makes Sweeping Exit From Bitcoin Mining Stocks: IREN Position Slashed 94%, Several Miners Liquidated